← 返回前沿论文

肾细胞癌中耗竭 TIL 内肿瘤反应性 TCR 揭示癌症类型特异性免疫景观

英文原题:Tumor-reactive TCRs within exhausted TILs reveal cancer type-specific immune landscapes in renal cell carcinoma.

查看英文原题

Tumor-reactive TCRs within exhausted TILs reveal cancer type-specific immune landscapes in renal cell carcinoma.

PubMed 2026/01/29(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

研究概要

这些发现揭示了ccRCC免疫景观的关键特征,并为优先筛选候选肿瘤反应性TCR提供了一个初步的概念验证转录组学框架。

中文摘要

透明细胞肾细胞癌(ccRCC)呈现出一种独特的免疫悖论:丰富的CD8+TIL(肿瘤浸润淋巴细胞)(TILs)与不良预后相关。为了阐明其功能状态和治疗潜力,我们对15例ccRCC患者的TILs进行了单细胞转录组分析,并利用自体肿瘤来源的类器官对优势T细胞受体(TCR)克隆型进行了功能验证。单细胞RNA测序揭示了T细胞组成的动态变化,在晚期肿瘤中,效应性和祖细胞耗竭型CD8+ T细胞减少,而终末耗竭型CD8+和调节性CD4+ T细胞富集。尽管存在这种耗竭表型,在一项纳入5例患者的探索性分析中,前20个TCR克隆型中约有一半在非耗竭T细胞中重新表达后仍保留抗肿瘤反应性,表现为TCR-T细胞介导的细胞毒性和针对自体类器官的IFN-产生。转录组特征使得开发一种惩罚逻辑回归分类器成为可能,该分类器能够以高准确度区分肿瘤反应性T细胞和旁观者T细胞,AUC分别为0.903(训练集)和0.913(测试集)。与胰腺导管腺癌(PDAC)数据集的跨癌种比较显示泛化性有限,凸显了需要癌种特异性模型的必要性。值得注意的是,ccRCC特异性TILs表现出成熟、功能分化的特征,增殖有限,与慢性抗原暴露一致,而PDAC反应性TILs则表现出高度增殖和活化的表型,提示正在进行的克隆扩增。总体而言,这些发现揭示了ccRCC免疫景观的关键特征,并为优先筛选候选肿瘤反应性TCR提供了一个初步的概念验证转录组学框架。这些见解表明,在ccRCC中识别候选TCR以用于未来开发基于TCR的过继性T细胞疗法是可行的,并强调了整合单细胞图谱分析与功能分析以优化免疫治疗策略的重要性。鉴于样本量有限,我们的结果应被视为探索性和假设生成性的,未来需要在更大规模的独立ccRCC队列中验证这些发现。

展开英文摘要原文

Clear cell renal cell carcinoma (ccRCC) presents a unique immunological paradox: abundant CD8 + tumor-infiltrating lymphocytes (TILs) correlate with poor prognosis. To clarify their functional status and therapeutic potential, we performed single-cell transcriptomic profiling of TILs from 15 patients with ccRCC and functionally validated dominant T cell receptor (TCR) clonotypes using autologous tumor-derived organoids. Single-cell RNA sequencing revealed dynamic shifts in T cell composition, with effector and progenitor-exhausted CD8 + T cells declining and terminally exhausted CD8 + and regulatory CD4 + T cells enriched in advanced tumors. Despite this exhausted phenotype, in an exploratory analysis with five patients, approximately half of the top 20 TCR clonotypes retained anti-tumor reactivity when re-expressed in non-exhausted T cells, as evidenced by TCR-T cell-mediated cytotoxicity and IFN- production against autologous organoids. Transcriptomic signatures enabled the development of a penalized logistic regression classifier that distinguished tumor-reactive from bystander T cells with high accuracy, with AUCs of 0.903 (training) and 0.913 (test). Cross-cancer comparison with pancreatic ductal adenocarcinoma (PDAC) datasets revealed limited generalizability, highlighting the need for cancer type-specific models. Notably, ccRCC-specific TILs exhibited mature, functionally differentiated profiles with limited proliferation, consistent with chronic antigen exposure, whereas PDAC-reactive TILs showed highly proliferative and activated phenotypes indicative of ongoing clonal expansion. Collectively, these findings suggest key features of the immune landscape in ccRCC and provide a preliminary, proof-of-concept transcriptomic framework for prioritizing candidate tumor-reactive TCRs. These insights suggest the feasibility of identifying candidate TCRs for future development of TCR-based adoptive T cell therapies in ccRCC and emphasize the importance of integrating single-cell profiling with functional analyses to refine immunotherapeutic strategies. Given the limited sample size, our results should be considered exploratory and hypothesis-generating, and future studies will be required to validate these findings in larger, independent ccRCC cohorts.

论文信息

作者
Komahashi M、Horaguchi S、Tsuji K、Hoshino D、Kishida T、Usui K、Nakaigawa N、Sato S
单位
Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.Japan
期刊
Frontiers in immunology2026
原文标识
PubMed 41694381 · DOI 10.3389/fimmu.2026.1729388